PT - JOURNAL ARTICLE AU - Marian Knight AU - Kathryn Bunch AU - Nicola Vousden AU - Eddie Morris AU - Nigel Simpson AU - Chris Gale AU - Patrick O’Brien AU - Maria Quigley AU - Peter Brocklehurst AU - Jennifer J Kurinczuk TI - Characteristics and outcomes of pregnant women hospitalised with confirmed SARS-CoV-2 infection in the UK: a national cohort study using the UK Obstetric Surveillance System (UKOSS) AID - 10.1101/2020.05.08.20089268 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.08.20089268 4099 - http://medrxiv.org/content/early/2020/05/12/2020.05.08.20089268.short 4100 - http://medrxiv.org/content/early/2020/05/12/2020.05.08.20089268.full AB - Objective To describe a national cohort of pregnant women hospitalised with SARS-CoV-2 infection in the UK, identify factors associated with infection and describe outcomes, including transmission of infection, for mother and infant.Design Prospective national population-based cohort study using the UK Obstetric Surveillance System (UKOSS).Setting All 194 obstetric units in the UKParticipants 427 pregnant women admitted to hospital with confirmed Sars-CoV-2 infection between 01/03/2020 and 14/04/2020. 694 comparison women who gave birth between 01/11/2017 and 31/10/2018.Main outcome measures Incidence of maternal hospitalisation, infant infection. Rates of maternal death, level 3 critical care unit admission, preterm birth, stillbirth, early neonatal death, perinatal death; odds ratios for infected versus comparison women.Results Estimated incidence of hospitalisation with confirmed SARS-CoV-2 in pregnancy 4.9 per 1000 maternities (95%CI 4.5-5.4). The median gestation at symptom onset was 34 weeks (IQR 29-38). Black or other minority ethnicity (aOR 4.49, 95%CI 3.37-6.00), older maternal age (aOR 1.35, 95%CI 1.01-1.81 comparing women aged 35+ with those aged 30-34), overweight and obesity (aORs 1.91, 95%CI 1.37-2.68 and 2.20, 95%CI 1.56-3.10 respectively compared to women with a BMI<25kg/m2) and pre-existing comorbidities (aOR 1.52, 95%CI 1.12-2.06) were associated with admission with SARS-CoV-2 during pregnancy. 247 women (58%) gave birth or had a pregnancy loss; 180 (73%) gave birth at term. 40 (9%) hospitalised women required respiratory support. Twelve infants (5%) tested positive for SARS-CoV-2 RNA, six of these infants within the first 12 hours after birth.Conclusions The majority of pregnant women hospitalised with SARS-CoV-2 were in the late second or third trimester, supporting guidance for continued social distancing measures in later pregnancy. Most had good outcomes and transmission of SARS-CoV-2 to infants was uncommon. The strong association between admission with infection and black or minority ethnicity requires urgent investigation and explanation.Study Registration ISRCTN 40092247Competing Interest StatementMK, MQ, PB, PO’B, JJK received grants from the NIHR in relation to the submitted work. KB, NV, NS, EM, CG have no conflicts of interest to declare.Clinical TrialISRCTN 40092247Clinical Protocols https://www.npeu.ox.ac.uk/downloads/files/ukoss/Pandemic%20Influenza%20%20COVID-19%20Protocol%20Version%203%20clean%20copy.pdf Funding StatementThe study was funded by the National Institute for Health Research HTA Programme (project number 11/46/12). MK is an NIHR Senior Investigator. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funder played no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. The corresponding author (MK) had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be shared according to the National Perinatal Epidemiology Unit data sharing policy https://www.npeu.ox.ac.uk/downloads/files/npeu/policies/Data%20Sharing%20Policy.pdf